Ticker

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that it is exploring discussions with third parties regarding the potential acquisition of additional assets in the central nervous system (CNS) space, with a specific focus on brain…

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurological condition without an FDA-approved therapeutic

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN - Get Free Report) fell 0.3% during mid-day trading on Tuesday. The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 421,599 shares. The stock had previously closed at $0.8317.

Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI)  Fully prepared to initiate near-term clinical site onboarding and first patient dosing in Australia Sarasota, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…

Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy